Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT-HF: Spironolactone in HFmrEF and HFpEF
NCT04727073Phase 3Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2018
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of spironolactone in heart failure with mid-range ejection fraction (HFmrEF), heart failure with preserved ejection fraction (HFpEF), sponsored by Charité – Universitätsmedizin Berlin. Started Nov 2018; status: terminated.
02
Drugs
spironolactone
03
Conditions
heart failure with mid-range ejection fraction (HFmrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT04727073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727073.